About: Norovirus antivirals: Where are we now?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Norovirus antivirals: Where are we now? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Norovirus antivirals: Where are we now?
Creator	White, Peter Daniel, \| Netzler, Natalie White, Correspondence, Peter Tuipulotu, Enosi
Source	Medline; PMC
abstract	Human noroviruses inflict a significant health burden on society and are responsible for approximately 699 million infections and over 200 000 estimated deaths worldwide each year. Yet despite significant research efforts, approved vaccines or antivirals to combat this pathogen are still lacking. Safe and effective antivirals are not available, particularly for chronically infected immunocompromised individuals, and for prophylactic applications to protect high‐risk and vulnerable populations in outbreak settings. Since the discovery of human norovirus in 1972, the lack of a cell culture system has hindered biological research and antiviral studies for many years. Recent breakthroughs in culturing human norovirus have been encouraging, however, further development and optimization of these novel methodologies are required to facilitate more robust replication levels, that will enable reliable serological and replication studies, as well as advances in antiviral development. In the last few years, considerable progress has been made toward the development of norovirus antivirals, inviting an updated review. This review focuses on potential therapeutics that have been reported since 2010, which were examined across at least two model systems used for studying human norovirus or its enzymes. In addition, we have placed emphasis on antiviral compounds with a defined chemical structure. We include a comprehensive outline of direct‐acting antivirals and offer a discussion of host‐modulating compounds, a rapidly expanding and promising area of antiviral research.
has issue date	2018-12-25(xsd:dateTime)
bibo:doi	10.1002/med.21545
bibo:pmid	30584800
has license	no-cc
sha1sum (hex)	e51d6319d4d82d9d48fbd705497304c5b3792cdc
schema:url	https://doi.org/10.1002/med.21545
resource representing a document's title	Norovirus antivirals: Where are we now?
has PubMed Central identifier	PMC7168425
has PubMed identifier	30584800
schema:publication	Med Res Rev
resource representing a document's body	covid:e51d6319d4d82d9d48fbd705497304c5b3792cdc#body_text
is schema:about of	named entity 'pathogen' named entity 'antivirals' named entity 'worldwide' named entity 'vaccines' named entity 'noroviruses' named entity 'Norovirus' named entity 'antivirals' named entity 'VPg' named entity 'chemical structure' named entity 'protease inhibitors' named entity 'antivirals' named entity 'antigenically variable' named entity 'VLPs' named entity 'norovirus' named entity 'murine' named entity 'feline calicivirus' named entity 'norovirus' named entity 'phase I clinical trials' named entity 'RdRp' named entity 'immunosuppressive drugs' named entity 'genome' named entity 'Asian' named entity 'placebo' named entity 'peer-reviewed' named entity 'antiviral' named entity 'homodimer' named entity 'norovirus' named entity 'DAAs' named entity 'antivirals' named entity 'chain termination' named entity 'X-ray crystallography' named entity 'RNA polymerase' named entity 'Vesivirus' named entity 'antiviral activity' named entity 'replication cycle' named entity 'infection' named entity 'replication cycle' named entity 'reverse-transcription polymerase chain reaction' named entity 'norovirus' named entity 'RdRp' named entity 'vaccine' named entity 'RdRp' named entity 'structural analysis' named entity 'norovirus' named entity 'norovirus' named entity 'infection' named entity 'norovirus' named entity 'receptor' named entity 'antiviral' named entity 'antiviral' named entity 'viral replication' named entity 'intracellular' named entity 'preclinical' named entity 'antiviral' named entity 'pathogen' named entity 'HBV' named entity 'antiviral' named entity 'norovirus' named entity 'preclinical development' named entity 'suramin' named entity 'nitazoxanide' named entity 'antivirals' named entity 'infection' named entity 'viral genome replication' named entity 'antivirals' named entity 'interact' named entity 'viral entry' named entity 'Lagovirus' named entity 'ORF1' named entity 'clinical trials' named entity 'NTP' named entity 'gastroenteritis' named entity 'Self-replicating' named entity 'norovirus' named entity 'genotypic' named entity 'capsid protein'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software